Intelligence ยท Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors โ phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text โ searchable for business development and competitive intelligence.
-
Jintrolongยฎ low dose group
The First People's Hospital of Lianyungang
Dwarfism
1 trial -
Jueyin granules
The First People's Hospital of Lianyungang
Psoriasis Vulgaris
1 trial -
KN046
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma
1 trial -
Kanglaite
The First People's Hospital of Lianyungang
Head and Neck Cancer
1 trial -
LBL-024 for Injection
The First People's Hospital of Lianyungang
Triple Negative Breast Cancer
1 trial -
LGD-6972-5 mg
LIGAND PHARMACEUTICALS INC
Type 2 Diabetes Mellitus
1 trial -
Lanthanum Polystyrene Sulphonate Powder
The First People's Hospital of Lianyungang
Hyperphosphatemia
1 trial -
Lasofoxifene
LIGAND PHARMACEUTICALS INC
Bone Loss
1 trial -
Lenalidomide
The First People's Hospital of Lianyungang
PTCL, NOS
1 trial -
Lenalidomide combined with G-CHOP (LO CHOP)
The First People's Hospital of Lianyungang
DLBCL - Diffuse Large B Cell Lymphoma
1 trial -
Lenvatinib
The First People's Hospital of Lianyungang
Biliary Tract Cancer
1 trial -
Lifei Qingchang Granules
The First People's Hospital of Lianyungang
Bronchiectasis
1 trial -
Linperlisib combination with obinutuzumab
The First People's Hospital of Lianyungang
Lymphoma
1 trial -
Liposomal irinotecan
The First People's Hospital of Lianyungang
Pancreatic Ductal Adenocarcinoma
1 trial -
Liposuction
The First People's Hospital of Lianyungang
Anterior Cruciate Ligament Partial Rupture
1 trial -
Luspatercept combined with low-dose thalidomide
The First People's Hospital of Lianyungang
Transfusion-dependent ฮฒ-thalassemia Patients
1 trial -
LysaKare 25 g/25 g solution for infusion, Lutathera 370 MBq/mL solution for infusion
Advanced Accelerator Applications
somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytoma and paragangliomas
1 trial -
MB07133
The First People's Hospital of Lianyungang
Safety Issues
1 trial -
MB07133 300mg/m2/day
LIGAND PHARMACEUTICALS INC
Hepatocellular Carcinoma
1 trial -
MB07803
LIGAND PHARMACEUTICALS INC
Type 2 Diabetes Mellitus
1 trial -
MB07811
LIGAND PHARMACEUTICALS INC
Hypercholesterolemia
1 trial -
MIE
The First People's Hospital of Lianyungang
Esophageal Cancer
1 trial -
MenSCs transplantation
The First People's Hospital of Lianyungang
Type 1 Diabetes Mellitus
1 trial -
Menstrual blood stem cells
The First People's Hospital of Lianyungang
Acute Lung Injury
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1โ3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync โ verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources